How Samsung Biologics is Paving the Way for Biopharmaceutical Companies

The biopharmaceutical industry was already one of the most impactful industries in the world before the COVID-19 pandemic, and now the public is more tuned-in than ever to what advances are being made by organizations who are working tirelessly to provide  better vaccines, better treatments, and better overall healthcare options for viruses, diseases, and ailments around the globe.

One of the most significant changes in the landscape of biopharmaceutical companies has been the growth  of Samsung Biologics, a CDMO and biopharmaceutical company that is expanding its business portfolio and production capacity to meet the varying needs of clients as well as the biopharma industry.  . Here’s everything you need to know about biopharmaceutical companies, and specifically what’s new from Samsung Biologics.

Introduction to Biopharmaceutical Companies and CDMOs

Biopharmaceutical companies develop and produce a range of drug products derived from biological sources, which have lower toxicity and side effects, and are much higher in efficacy to target specific chronic illnesses such as cancer, autoimmune disease, and Alzheimer’s disease, etc.. Whether manufacturing more effective cancer treatments or helping combat the COVID-19 pandemic with novel vaccines, biopharmaceutical companies like Samsung Biologics are at the forefront of making the world healthier and safer.

Samsung Biologics is a CDMO, or contract manufacturing and development organization, meaning that they partner with existing organizations to help expand their capabilities through specific contracted services. Recently,  Samsung Biologics and one of the most high-profile biopharmaceutical companies entered into a partnership to deliver potentially life-saving COVID-19 vaccines.

Partnering with Moderna to Combat COVID-19

It was recently announced that Samsung would partner with high-profile COVID-19 vaccine manufacturer Moderna to provide fill-finish capabilities. Samsung Biologics will provide aseptic fill-finish, labelling, and packaging services for the biopharmaceutical company.

“This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine,” said John Rim, CEO of Samsung Biologics. “Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.”

Certifications that Stand for More than a Benchmark

Global certifications in the biopharmaceutical industry are about more than having something to hang on office walls. These certifications ensure the highest level of commitment to environmentally minded practices and other vital areas of focus that  many organizations strive for. That makes Samsung Biologics’ recent attainment of not one but four certifications significant.

“We are extremely proud to obtain four global ISO certifications during a time where a high degree sustainable management system is vital, especially in light of COVID-19, to stably operate and supply crucial biomedicines for patients,” John Rim commented. “Samsung Biologics is a leading CDMO committed to taking responsibility and consideration of ESG factors across all of our business areas, and we will continue to enhance our capabilities to meet the evolving needs of clients whilst ensuring the safety and security of not only our people but also of the environment to ultimately create a better future for humanity.”